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Abstract

Atrial fibrillation is a commonly encountered pathology in medical practice, and its
prevalence has shown a continuous rise over the past years. Atrial fibrillation has a
significant impact on patients' quality of life, not only due to the standard anticoagulant
treatment with vitamin K antagonists that require close monitoring and dose adjustment,
but also due to the fragile equilibrium between hemorrhagic and thrombotic risks. The
introduction of new oral anticoagulants (NOACs) in the treatment guidelines for atrial
fibrillation has improved the quality of life, as NOACs do not require close monitoring
or dose adjustments. However, even if the safety profile of the NOACs regarding the
hemorrhagic risk is superior to vitamin K antagonists, the problem raised by an
unexpected hemorrhage (e.g. severe hemorrhage after an accident) and the need for
efficient hemostasis in a chronic anticoagulated patient has remained unsolved. To find
a solution for this problem, reversal agents for NOACs have been developed and tested,
and two of them, idarucizumab and andexanet-alpha, have already been approved by the
FDA, thus making NOACs increasingly appealing as a choice of anticoagulation
treatment.
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Highlights

✓

Long-term oral anticoagulant therapy includes vitamin K antagonists and new oral
anticoagulants (NOACs).

✓

The introduction of NOACs in the treatment guidelines for atrial fibrillation has improved
the quality of life of patients, as they do not require close monitoring or dose adjustments.

✓

NOACs are divided into two broad categories, depending on the mechanism of action:
substances that directly inhibit the activity of thrombin (e.g. dabigatran) and substances
that directly inhibit activated factor X (e.g. rivaroxaban, apixaban, edoxaban).
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Introduction

Table 1. CHA2DS2-VASC score

Atrial fibrillation – epidemiological data
Atrial fibrillation is a frequent pathology in medical
practice, which despite treatment and careful
management, remains the primary cause of heart failure,
stroke, and even sudden death (1-3).
Epidemiological data show a rise in the prevalence
and incidence of this pathology (1). This could be due to
easier detection of atrial fibrillation, access to ECG
devices, and the possibility of ECG-Holter monitoring,
thus discovering paroxysmal atrial fibrillation episodes
otherwise undiagnosed.

Points
1

Congestive heart failure

1

Hypertension

2

Age ≥ 75 years

1

Diabetes mellitus

2

Stroke/ Transient Ischemic Attack/
Thromboembolic event

1

Vascular disease (prior Myocardial
Infarction, Peripheric Arterial Disease
or Aortic Plaque)

1

Age 65 to 74 years

1

Sex category (female sex)

Global life expectancy has grown significantly
between the years 1970 and 2015 (4), in some countries
even up to 20 years, with average life expectancy around
80 years at the European level (5). This implies a global

CHA2DS2-VASC

increase in the prevalence of the elderly population, as
The HAS-BLED (Table 2) score assesses
well as of the chronic diseases associated with ageing,
hemorrhagic risk. A high score is not a contraindication
that increase the risk of developing atrial fibrillation
for anticoagulant treatment, but rather indicates the need
(e.g. hypertension, ischemic heart disease, valvular
for accurate detection and subsequent removal of the
diseases, etc.). Atrial fibrillation in Europe is estimated
modifiable hemorrhagic risk factors. Modifiable
at 3% in adults older than 20 years, with an expected
hemorrhagic risk factors are uncontrolled arterial
number of 14-17 million patients by 2030 in the
hypertension (especially a systolic blood pressure > 160
European Union (6-8).
mmHg), a labile INR or a therapeutic INR in less than
Anticoagulant medication in patients with atrial 60% of the time, usage of medication that predisposes to
fibrillation
bleeding, or excess alcohol usage (13, 14).
A major complication of atrial fibrillation is the
increased risk of stroke. An essential objective in the Table 2. HAS-BLED score.
treatment of atrial fibrillation is the prevention of stroke
by using oral anticoagulant therapy (9). Long-term oral
anticoagulant therapy includes vitamin K antagonists
and new oral anticoagulants that should be personalized
for each patient according to comorbidities in order to

Points

HAS-BLED

1

Hypertension (uncontrolled, systolic
blood pressure >160 mmHg)

1

Abnormal renal function

1

Abnormal liver function

The decision to anticoagulate a patient should take
into consideration two scores for the assessment of
thrombotic risk and hemorrhagic risk (9).

1

Stroke

1

Bleeding

The CHA2DS2-VASC score evaluates the risk of
stroke in patients with non-valvular atrial fibrillation.
CHA2DS2-VASC is calculated adding the points
according to the presence of some major risk factors for

1

Labile INR

1

Age > 65 years

1

Prior alcohol (≥ 8 drinks/week) or drug
usage history

1

Medication usage predisposing to
bleeding (antiplatelet agents, NSAIDs)

achieve a balance between thrombotic and hemorrhagic
risk (10).

stroke (Table 1). Anticoagulation therapy should be
reconsidered in patients with a CHA2DS2-VASC score
≥ 1 and is indicated at a score ≥ 2 (11, 12).
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Discussions
According to the latest European Society of
Cardiology guideline, oral anticoagulant therapy is
recommended only in non-valvular atrial fibrillation and
is not recommended in patients with valvular atrial
fibrillation (atrial fibrillation in patients with mitral
stenosis or prosthetic valve) (8). In deciding the
anticoagulant treatment, the comorbidities of the patient
play a very important role (15-17).
New oral anticoagulants
These molecules have been developed because of
the multiple disadvantages of vitamin K antagonists.
Vitamin K antagonists (warfarin, acenocoumarol) have
a long duration of action, with a long half-life and an

symptoms. A possible explanation may be the tartaric
acid, a component of the capsule, which is intended to
provide a lower pH and better absorption at the digestive
level (18). Dabigatran has predominantly renal
elimination (80%); it is not recommended in patients
with a creatinine clearance (CrCl) between 30-59
mL/min and is contraindicated in patients with CrCl less
than 30mL/min (19, 20).
Rivaroxaban, according to the ROCKET-AF study,
is also non-inferior to warfarin, with similar rates of
stroke and systemic embolism prevention and of
hemorrhagic risk (21). However, in the group of patients
treated with rivaroxaban, a lower incidence of
intracranial hemorrhage was observed and a greater
frequency of digestive hemorrhage. The usual dose of

unpredictable anticoagulant effect that requires careful rivaroxaban is a single dose of 20 mg per day or 10
and constant monitoring by checking the value of INR mg/day for patients with a CrCl of 15-49 mL/min (21,
and adjusting doses accordingly. New oral 22).
Apixaban has been shown in the ARISTOTLE
anticoagulants have been synthesized as a higher-safety
therapeutic option. These are divided into two broad study to be superior to warfarin regarding stroke
categories, depending on the mechanism of action: prevention (18). Compared to warfarin, apixaban had
substances that directly inhibit the activity of thrombin lower rates of bleeding of any type, both intracranial
(e.g. dabigatran) and substances that directly inhibit
activated factor X (e.g. rivaroxaban, apixaban,
edoxaban). These new classes of anticoagulants have the
advantage of a more predictable anticoagulant effect,
fixed doses, and not requiring INR monitoring. In
addition, studies have demonstrated the superior safety
profile of the new anticoagulants compared to warfarin
in the case of non-valvular atrial fibrillation (18).

hemorrhages and gastrointestinal bleeding, and is the
only NOAC that shows significantly lower rates of all
types of bleeding (23). Also, the group of patients
treated with apixaban had a lower incidence of
myocardial infarction than the group treated with
warfarin. This result could be an advantage of apixaban
compared to dabigatran, which had a higher incidence
of myocardial infarction compared to the warfarin-

NOACs offer a superior safety profile compared with treated group. The standard dose of apixaban is 5 mg
cumarinic anticoagulants in patients who need surgical twice daily, apixaban being the NOAC with the lowest
interventions, with a shorter presurgery interrupting percentage of renal elimination (25%) (23). A lower
dose to 2.5 mg twice daily is recommended if at least
Dabigatran, the first approved NOAC, was two of the three criteria are present: age > 80 years,
introduced following the results of the RE-LY study weight < 60 kg or serum creatinine > 1.5 mg/dL (24).
The latest NOAC is edoxaban, which was
(18). The dose of dabigatran is 110 mg twice daily or
period.

150 mg twice daily, the study demonstrating that both
doses are non-inferior to warfarin. Compared to
warfarin, dabigatran 110 mg, administered twice daily,
demonstrated a lower rate of major hemorrhage, with
similar per cent of stroke or systemic embolism (18).
Administered 150 mg twice daily, dabigatran had
similar major bleeding rates to warfarin, but lower rates
of stroke or systemic embolism (18). The daily dose of

compared to warfarin in the ENGAGE-AF-TIMI study
(25). Edoxaban has two dose regimens: high (a single
daily dose of 60 mg) or low (a single daily dose of 30
mg). Edoxaban proved to be non-inferior to warfarin
regarding the prevention of ischemic stroke and
systemic emboli, with a higher incidence of ischemic
stroke when taken in a low-dose regimen, and a lower
incidence when taken in the high-dose regimen (25).

dabigatran depends on the age and comorbidities of the Both dose regimens demonstrate a significant decrease
both intracranial
patient. Treatment with dabigatran has been associated in bleeding complications,
with a higher rate of digestive hemorrhage and dyspeptic hemorrhages and fatal hemorrhages, the only exception
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being gastrointestinal hemorrhages that have a higher
frequency only in the high-dose regimen group (25). An
important drug interaction occurs with glycoprotein P
inhibitors, such as verapamil or quinidine, so, in case of
concomitant medication with these drugs, the dose of
edoxaban should be reduced by half. Edoxaban is not
recommended in patients with CrCl <30 mL/min. Doses

in Europe and is indicated in life-threatening bleedings
or emergency surgery, in patients with chronic
anticoagulant therapy with dabigatran (34).
In patients receiving preprocedural idarucizumab,
efficient periprocedural hemostasis was obtained in
93.4% of the cases (33). In addition, administration of
idarucizumab does not expose to an additional

should be adjusted for patients with a CrCl between 1549 mL/min, at 30 or 15 mg per day (25, 26).
All NOACs have demonstrated a superior safety
profile or at least non-inferior to warfarin regarding
hemorrhagic risk, and are at least non-inferior to
warfarin in the prevention of ischemic stroke and
systemic embolism. However, the frequency of
digestive hemorrhage was higher in patients treated with

procoagulant post-administration risk, the risk
depending on the pre-existing risk factors of each
patient. Only 4.8% of patients had thrombotic events
within 30 days after idarucizumab administration (33).
Idarucizumab can be administered regardless of the
renal function, without the need for dose adjustment.
One drawback is the lack of data regarding the use of
idarucizumab in patients younger than 18 years old and

dabigatran, rivaroxaban, or edoxaban compared to in pregnant women.
patients treated with warfarin, apixaban being the
Also, immunogenic reactions may occur after
NOAC with the lowest frequency of all types of administration of idarucizumab. So far, no allergic
hemorrhage, including gastrointestinal bleedings (27). reactions to idarucizumab have been reported, but some
The NOACs are not recommended in patients with cases of immunogenic reactions with anti-idarucizumab
severe renal dysfunction. A major drawback has been, antibodies production have been reported, without
until recently, the lack of an antidote, with the affecting the response in case of a future administration
impossibility of stopping the anticoagulant effect in case
of severely fatal bleeding (for example following severe
trauma, the need of an emergency or urgent operation,
etc.) (28, 29). Numerous surgical interventions,
especially pelvic surgery, in both men and women, even
not major, are associated with intraoperative blood
losses (30). Elimination of NOACs is realized at the
renal level, so kidney function must be carefully

(34). However, the data regarding these situations is
limited and remains the subject of future studies.
Andexanet Alfa is a recombinant modified human
factor Xa molecule and is the second reversal molecule,
recently approved by the FDA, against rivaroxaban and
apixaban. According to the Andexanet-Alfa 4 study, it
demonstrated its efficacy on both rivaroxaban and
apixaban, without significant adverse effects (35).

monitored during treatment with NOACs by monitoring Andexanet Alfa was administered depending on the last
the serum creatinine, both preoperative and dose of anticoagulant taken by the patient: if the last
dose was administered more than 7 hours before, then
postoperative (31).
400 mg of Andexanet Alfa had been given as a bolus,
New perspectives in the acute treatment of
followed by 480 mg during 2 hours infusion. If the last
hemorrhage in patients taking NOACs: reversal agents
dose of anticoagulant was taken less than 7 hours or if
Idarucizumab and Andexanet Alpha
the last dose was unknown, then 800 mg of Andexanet
To counter the anticoagulant effects of NOACs in Alfa had been given as a bolus, followed by 960 mg
case of acute bleeding, the reversal agents idarucizumab during 2 hours infusion (35). Effective hemostasis was
and andexanet alpha were recently introduced on the reached 12 hours after infusion with Andexanet Alfa,
market.
being present in 79% of the study population. At 30 days
Idarucizumab is a monoclonal antibody that acts post-administration, thrombotic events occurred in 18%
against dabigatran and was introduced on the market of patients, and the mortality rate was 15% (35).
Ciraparantag is a new reversing agent, which is the
following the results of a REVERSE-AD study (32).
Idarucizumab is given in a total dose of 5 g, divided into subject of the currently undergoing study "Phase 2
two 50 mL bolus infusions, over 10-15 minutes. Its Placebo-Controlled, Single-Site, Single-Blind Study of
effect is fast, the median time to reversing the effect Rivaroxaban Reversal by Ciraparantag as Measured by
being 2.5 hours (33). Idarucizumab has been approved WBCT" (36). Ciraparantag is a water-soluble molecule
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that binds heparin and direct factor Xa and IIa inhibitors, 8. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar
D, Casadei B, Castella M, Diener HC, Heidbuchel
which had promising results in phase I studies,
H, Hindricks JHG, Manolis AS, Oldgren J, Popescu
managing to reverse anticoagulation due to edoxaban
BA, Schotten U, Van Putte B, Vardas P. 2016 ESC
after a dose of 100-300 mg (36).
Guidelines for the management of atrial fibrillation
developed in collaboration with EACTS. Eur Heart
Conclusions
J. 2016; 37(38): 2893–962. PMID: 27567408, DOI:
NOACs have entered the clinical practice, being
10.1093/eurheartj/ehw210
recommended
by
international
guidelines, 9. Gallego P, Roldán V, Torregrosa JM, Gálvez J,
demonstrating their efficacy and superior safety profile
Valdés M, Vicente V, Marín F, Lip GY. Relation of
compared to warfarin. The emergence and approval of
the HAS-BLED bleeding risk score to major
the new molecules, idarucizumab and andexanet alfa,
bleeding, cardiovascular events and mortality in
solve one of the most important drawbacks of NOACs,
patients with atrial fibrillation. Circ Arrhythm
Electrophysiol. 2012; 5(2): 312–318. PMID:
the absence of a reversal agent, and provides the
22319005, DOI: 10.1161/CIRCEP.111.967000
opportunity for better control of life-threatening
bleedings or uncontrollable hemorrhages in emergency 10. Wittkowsky AK. Novel oral anticoagulants and their
role in clinical practice. Pharmacotherapy. 2011;
surgeries, for patients who follow chronic treatment
31(12): 1175–91. PMID: 22122180, DOI:
with NOACs (37, 38).
10.1592/phco.31.12.1175
11. Lutz J, Jurk K, Schinzel H. Direct oral
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